Press Releases Candel Therapeutics, Inc.

Equities

CADL

US1374041093

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
8.55 ^USD	+9.62%		-30.32%	+481.63%

May. 23	Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of Can-2409 for Advanced Non-Small Cell Lung Cancer in Patients Non-Responsive to Immune Checkpoint Inhibitor Treatment At 2024 Asco Annual Meeting	CI
Apr. 11	Sector Update: Health Care Stocks Decline Thursday Afternoon	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Candel Therapeutics : Corporate Presentation - May 2024	May. 24	PU
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting	May. 23	GL
Candel Therapeutics to Present at the Jefferies Global Healthcare Conference	May. 22	GL
Candel Therapeutics to Present at the Jefferies Global Healthcare Conference	May. 22	AQ
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting	May. 20	GL
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting	May. 20	AQ
Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights	May. 14	GL
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting	Apr. 25	GL
Autonomix Medical Inc Covered in Benzinga Article Highlighting Innovative Nerve Treatment Tech	Apr. 16	AQ
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer	Apr. 11	GL
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors	Apr. 09	GL
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer	Apr. 04	GL
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma	Mar. 28	GL
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights	Mar. 28	GL
Candel Therapeutics : Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights - Form 8-K	Mar. 28	PU
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate	Mar. 05	GL
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate	Mar. 05	AQ
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma	Feb. 13	GL
Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts	Feb. 05	GL
Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts	Feb. 05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Candel Therapeutics, Inc.

Equities

CADL

US1374041093

Press Releases

Filters